Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-11-06

FDA Approved: GILOTRIF — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for GilotrIF (afatinib) filed by Boehringer Ingelheim Pharmaceuticals, Inc. The action appears to modify the drug's …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gilotrif (Afatinib)

Snippet

SUPPL AP for GILOTRIF (AFATINIB)